Ligand Pharmaceuticals announced the launch of Pelthos Therapeutics, a biopharmaceutical company, and the appointment of seasoned industry executive Scott Plesha to the role of Chief Executive Officer. Plesha brings to his role more than 30 years of experience in the pharmaceutical industry, including two decades building and leading specialty pharmaceutical commercial organizations. Prior to joining Pelthos, Plesha was President and Chief Commercial Officer at BioDelivery Sciences until it was acquired by Collegium Pharmaceutical in 2022.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
